Neprilysin Explained

Neprilysin (; also known as membrane metallo-endopeptidase (MME), neutral endopeptidase (NEP), cluster of differentiation 10 (CD10) and common acute lymphoblastic leukemia antigen (CALLA)) is an enzyme that in humans is encoded by the MME gene. Neprilysin is a zinc-dependent metalloprotease that cleaves peptides at the amino side of hydrophobic residues and inactivates several peptide hormones including glucagon, enkephalins, substance P, neurotensin, oxytocin, and bradykinin.[1] It also degrades the amyloid beta peptide whose abnormal folding and aggregation in neural tissue has been implicated as a cause of Alzheimer's disease. Synthesized as a membrane-bound protein, the neprilysin ectodomain is released into the extracellular domain after it has been transported from the Golgi apparatus to the cell surface.

Neprilysin is expressed in a wide variety of tissues and is particularly abundant in kidney. It is also a common acute lymphocytic leukemia antigen that is an important cell surface marker in the diagnosis of human acute lymphocytic leukemia (ALL). This protein is present on leukemic cells of pre-B phenotype, which represent 85% of cases of ALL.[1]

Hematopoietic progenitors expressing CD10 are considered "common lymphoid progenitors", which means they can differentiate into T, B or natural killer cells.[2] CD10 is of use in hematological diagnosis since it is expressed by early B, pro-B and pre-B lymphocytes, and by lymph node germinal centers.[3] Hematologic diseases in which it is positive include ALL, angioimmunoblastic T cell lymphoma, Burkitt lymphoma, chronic myelogenous leukemia in blast crisis (90%), diffuse large B-cell lymphoma (variable), follicular center cells (70%), hairy cell leukemia (10%), and myeloma (some). It tends to be negative in acute myeloid leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, and marginal zone lymphoma. CD10 is found on non-T ALL cells, which derive from pre-B lymphocytes, and in germinal center-related non-Hodgkin lymphoma such as Burkitt lymphoma and follicular lymphoma, but not on leukemia cells or lymphomas, which originate in more mature B cells.[4]

Amyloid beta regulation

Neprilysin-deficient knockout mice show both Alzheimer's-like behavioral impairment and amyloid-beta deposition in the brain,[5] providing strong evidence for the protein's association with the Alzheimer's disease process. Because neprilysin is thought to be the rate-limiting step in amyloid beta degradation,[6] it has been considered a potential therapeutic target; compounds such as the peptide hormone somatostatin have been identified that increase the enzyme's activity level.[7] Declining neprilysin activity with increasing age may also be explained by oxidative damage, known to be a causative factor in Alzheimer's disease; higher levels of inappropriately oxidized neprilysin have been found in Alzheimer's patients compared to cognitively normal elderly people.[8]

Signaling peptides

Neprilysin is also associated with other biochemical processes, and is particularly highly expressed in kidney and lung tissues. Inhibitors have been designed with the aim of developing analgesic and antihypertensive agents that act by preventing neprilysin's activity against signaling peptides such as enkephalins, substance P, endothelin, and atrial natriuretic peptide.[9] [10]

Associations have been observed between neprilysin expression and various types of cancer; however, the relationship between neprilysin expression and carcinogenesis remains obscure. In cancer biomarker studies, the neprilysin gene is often referred to as CD10 or CALLA. In some types of cancer, such as metastatic carcinoma and some advanced melanomas, neprilysin is overexpressed;[11] in other types, most notably lung cancers, neprilysin is downregulated, and thus unable to modulate the pro-growth autocrine signaling of cancer cells via secreted peptides such as mammalian homologs related to bombesin.[12] Some plant extracts (methanol extracts of Ceropegia rupicola, Kniphofia sumarae, Plectranthus cf barbatus, and an aqueous extract of Pavetta longiflora) were found able to inhibit the enzymatic activity of neutral endopeptidase.[13]

Inhibitors

Inhibitors have been designed with the aim of developing analgesic and antihypertensive agents that act by preventing neprilysin's activity against signaling peptides such as enkephalins, substance P, endothelin, and atrial natriuretic peptide.[9] [10]

Some are intended to treat heart failure.

Other dual inhibitors of NEP with ACE/angiotensin receptor were (in 2003) being developed by pharmaceutical companies.[15]

Immunochemistry

CD10 is used in clinical pathology for diagnostic purpose.

In lymphomas and leukemias

In epithelial tumors

In other tumors

See also

External links

Notes and References

  1. Web site: Entrez Gene: Membrane metallo-endopeptidase .
  2. Galy A, Travis M, Cen D, Chen B . Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset . Immunity . 3 . 4 . 459–473 . October 1995 . 7584137 . 10.1016/1074-7613(95)90175-2 . free .
  3. Web site: CD10 . Singh C . 2011-02-25 . CD Markers . PathologyOutlines.com, Inc. .
  4. Papandreou CN, Nanus DM . Is methylation the key to CD10 loss? . J. Pediatr. Hematol. Oncol. . 32 . 1 . 2–3 . January 2010 . 20051779 . 10.1097/MPH.0b013e3181c74aca . free .
  5. Madani R, Poirier R, Wolfer DP, Welzl H, Groscurth P, Lipp HP, Lu B, El Mouedden M, Mercken M, Nitsch RM, Mohajeri MH . Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo . J. Neurosci. Res. . 84 . 8 . 1871–8 . December 2006 . 16998901 . 10.1002/jnr.21074 . 46527377 .
  6. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC . Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition . Nat. Med. . 6 . 2 . 143–50 . February 2000 . 10655101 . 10.1038/72237 . 22431826 .
  7. Iwata N, Higuchi M, Saido TC . Metabolism of amyloid-beta peptide and Alzheimer's disease . Pharmacol. Ther. . 108 . 2 . 129–48 . November 2005 . 16112736 . 10.1016/j.pharmthera.2005.03.010 . free .
  8. Wang DS, Iwata N, Hama E, Saido TC, Dickson DW . Oxidized neprilysin in aging and Alzheimer's disease brains . Biochem. Biophys. Res. Commun. . 310 . 1 . 236–41 . October 2003 . 14511676 . 10.1016/j.bbrc.2003.09.003 .
  9. Sahli S, Stump B, Welti T, Schweizer WB, Diederich R, Blum-Kaelin D, Aebi JD, Böhm HJ . April 2005 . A New Class of Inhibitors for the Metalloprotease Neprilysin Based on a Central Imidazole Scaffold . . 88 . 4 . 707–730 . 10.1002/hlca.200590050 . free .
  10. Oefner C, Roques BP, Fournie-Zaluski MC, Dale GE . Structural analysis of neprilysin with various specific and potent inhibitors . Acta Crystallogr. D . 60 . Pt 2 . 392–6 . February 2004 . 14747736 . 10.1107/S0907444903027410 .
  11. Velazquez EF, Yancovitz M, Pavlick A, Berman R, Shapiro R, Bogunovic D, O'Neill D, Yu YL, Spira J, Christos PJ, Zhou XK, Mazumdar M, Nanus DM, Liebes L, Bhardwaj N, Polsky D, Osman I . Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma . J Transl Med . 5 . 1. 2 . 2007 . 17207277 . 1770905 . 10.1186/1479-5876-5-2 . free .
  12. Cohen AJ, Bunn PA, Franklin W, Magill-Solc C, Hartmann C, Helfrich B, Gilman L, Folkvord J, Helm K, Miller YE . Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux . Cancer Res. . 56 . 4 . 831–9 . February 1996 . 8631021 .
  13. Alasbahi R, Melzig MF . Screening of some Yemeni medicinal plants for inhibitory activity against peptidases . Pharmazie . 63 . 1 . 86–8 . January 2008 . 18271311 . 10.1055/s-2008-1047849.
  14. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR . Angiotensin-neprilysin inhibition versus enalapril in heart failure . The New England Journal of Medicine . 371 . 11 . 993–1004 . Sep 2014 . 25176015 . 10.1056/NEJMoa1409077 . 10993/27659. 11383 . free .
  15. Venugopal J . Pharmacological modulation of the natriuretic peptide system . Expert Opinion on Therapeutic Patents . 13 . 9 . 1389–1409 . 2003 . 10.1517/13543776.13.9.1389. 85007768 .
  16. McGowan P, Nelles N, Wimmer, J, Williams D, Wen J, Li M, Ewton A, Curry C, Zu Y, Sheehan A, Chang CC . Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: the role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system . . 137 . 4 . 665–70 . 2012 . 22431545 . 10.1309/AJCP3FEPX5BEEKGX . 4975158 .
  17. Berglund M, Thunberg U, Amini RM, Book M, Roos G, Erlanson M, Linderoth J, Dictor M, Jerkeman M, Cavallin-Ståhl E, Sundström C, Rehn-Eriksson S, Backlin C, Hagberg H, Rosenquist R, Enblad G . Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis . Mod. Pathol. . 18 . 8 . 1113–20 . 2005 . 15920553 . 10.1038/modpathol.3800396 . 7563005 . free .
  18. Höller S, Horn H, Lohr A, Mäder U, Katzenberger T, Kalla J, Bernd HW, Went P, Ott MM, Müller-Hermelink HK, Rosenwald A, Ott G . A cytomorphological and immunohistochemical profile of aggressive B-cell lymphoma: high clinical impact of a cumulative immunohistochemical outcome predictor score . J. Hematopathol. . 2 . 4 . 187–94 . 2009 . 20309427 . 2798934 . 10.1007/s12308-009-0044-x .
  19. Xu Y, McKenna RW, Molberg KH, Kroft SH . Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma: Identification of a high-risk subset with coexpression of CD10 and bcl-2 . American Journal of Clinical Pathology . 116 . 2 . 183–90 . 2001 . 11488064 . 10.1309/J7RN-UXAY-55GX-BUNK . free .
  20. Fabiani B, Delmer A, Lepage E, Guettier C, Petrella T, Brière J, Penny AM, Copin MC, Diebold J, Reyes F, Gaulard P, Molina TJ . CD10 expression in diffuse large B-cell lymphomas does not influence survival . Virchows Arch. . 445 . 6 . 545–51 . 2004 . 15517363 . 10.1007/s00428-004-1129-7 . 23189608 .
  21. Baseggio L, Traverse-Glehen A, Berger F, Ffrench M, Jallades L, Morel D, Goedert G, Magaud JP, Salles G, Felman P . CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic T-cell lymphoma . Mod. Pathol. . 24 . 7 . 993–1003 . 2011 . 21499231 . 10.1038/modpathol.2011.53 . 22353148 . free .
  22. Yuan CM, Vergilio JA, Zhao XF, Smith TK, Harris NL, Bagg A . CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry . Hum. Pathol. . 36 . 7 . 784–91 . 2005 . 16084948 . 10.1016/j.humpath.2005.05.008 .
  23. Attygalle AD, Diss TC, Munson P, Isaacson PG, Du MQ, Dogan A . CD10 expression in extranodal dissemination of angioimmunoblastic T-cell lymphoma . Am. J. Surg. Pathol. . 28 . 1 . 54–61 . 2004 . 14707864 . 10.1097/00000478-200401000-00005. 25639416 .
  24. Cook JR, Craig FE, Swerdlow SH . Benign CD10-positive T cells in reactive lymphoid proliferations and B-cell lymphomas . Mod. Pathol. . 16 . 9 . 879–85 . 2003 . 13679451 . 10.1097/01.MP.0000084630.64243.D1 . 21020212 . free .
  25. Yasir S, Herrera L, Gomez-Fernandez C, Reis IM, Umar S, Leveillee R, Kava B, Jorda M . CD10+ and CK7/RON- immunophenotype distinguishes renal cell carcinoma, conventional type with eosinophilic morphology from its mimickers . Appl. Immunohistochem. Mol. Morphol. . 20 . 5 . 454–61 . 2012 . 22417859 . 10.1097/PAI.0b013e31823fecd3 . 1348915 .
  26. Notohara K, Hamazaki S, Tsukayama C, Nakamoto S, Kawabata K, Mizobuchi K, Sakamoto K, Okada S . Solid-pseudopapillary tumor of the pancreas: immunohistochemical localization of neuroendocrine markers and CD10 . Am. J. Surg. Pathol. . 24 . 10 . 1361–71 . 2000 . 11023097 . 10.1097/00000478-200010000-00005. 3211829 .
  27. Córdoba A, Guerrero D, Larrinaga B, Iglesias ME, Arrechea MA, Yanguas JI . Bcl-2 and CD10 expression in the differential diagnosis of trichoblastoma, basal cell carcinoma, and basal cell carcinoma with follicular differentiation . Int. J. Dermatol. . 48 . 7 . 713–7 . 2009 . 19570076 . 10.1111/j.1365-4632.2009.04076.x . 205395744 .
  28. Sari Aslani F, Akbarzadeh-Jahromi M, Jowkar F . Value of CD10 Expression in Differentiating Cutaneous Basal from Squamous Cell Carcinomas and Basal Cell Carcinoma from Trichoepithelioma . Iran J Med Sci . 38 . 2 . 100–6 . 2013 . 23825889 . 3700055 .
  29. Murali R, Delprado W . CD10 immunohistochemical staining in urothelial neoplasms . American Journal of Clinical Pathology . 124 . 3 . 371–9 . 2005 . 16191505 . 10.1309/04BH-F6A8-0BQM-H7HT . free .
  30. Bahadir B, Behzatoglu K, Bektas S, Bozkurt ER, Ozdamar SO . CD10 expression in urothelial carcinoma of the bladder . Diagn. Pathol. . 4 . 1. 38 . 2009 . 19917108 . 2780995 . 10.1186/1746-1596-4-38 . free .
  31. Mikami Y, Hata S, Kiyokawa T, Manabe T . Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study . Mod. Pathol. . 15 . 9 . 923–30 . 2002 . 12218209 . 10.1097/01.MP.0000026058.33869.DB . 30632093 . free .
  32. McCluggage WG, Sumathi VP, Maxwell P . CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms . Histopathology . 39 . 3 . 273–8 . 2001 . 11532038 . 10.1046/j.1365-2559.2001.01215.x. 42287024 . free .
  33. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S . Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer . J. Clin. Oncol. . 23 . 16 . 3706–12 . 2005 . 15867200 . 10.1200/JCO.2005.00.232 . free .
  34. Weinreb I, Cunningham KS, Perez-Ordoñez B, Hwang DM . CD10 is expressed in most epithelioid hemangioendotheliomas: a potential diagnostic pitfall . Arch. Pathol. Lab. Med. . 133 . 12 . 1965–8 . 2009 . 19961253 . 10.5858/133.12.1965 .
  35. Jung SM, Kuo TT . Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear cell renal cell carcinoma . Mod. Pathol. . 18 . 6 . 788–94 . 2005 . 15578072 . 10.1038/modpathol.3800351 . 16510470 . free .
  36. Yin WH, Li J, Chan JK . Sporadic haemangioblastoma of the kidney with rhabdoid features and focal CD10 expression: report of a case and literature review . Diagn. Pathol. . 7 . 1. 39 . 2012 . 22497861 . 3364142 . 10.1186/1746-1596-7-39 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Neprilysin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.